R. Coleman Lindsley
Harvard University
ImmunologyMyeloid leukemiaMyeloidMedicineBiology
What is this?
Publications 74
#1Neha Nagpal (Harvard University)H-Index: 7
Last. Christopher F. Reilly (Harvard University)H-Index: 6
view all 17 authors...
Genetic lesions that reduce telomerase activity inhibit stem cell replication and cause a range of incurable diseases, including dyskeratosis congenita (DC) and pulmonary fibrosis (PF). Modalities to restore telomerase in stem cells throughout the body remain unclear. Here, we describe small-molecule PAPD5 inhibitors that demonstrate telomere restoration in vitro, in stem cell models, and in vivo. PAPD5 is a non-canonical polymerase that oligoadenylates and destabilizes telomerase RNA component ...
#1Christopher J. Gibson (Harvard University)H-Index: 17
#2R. Coleman Lindsley (Harvard University)H-Index: 22
#1Andrew M. Brunner (Harvard University)H-Index: 14
#2Traci M. Blonquist (Harvard University)H-Index: 11
Last. Amir T. Fathi (Harvard University)H-Index: 29
view all 45 authors...
Summary Background Increased aurora A kinase (AAK) expression occurs in acute myeloid leukaemia; AAK inhibition is a promising therapeutic target in this disease. We therefore aimed to assess the activity of alisertib combined with 7 + 3 induction chemotherapy in previously untreated patients with high-risk acute myeloid leukaemia. Methods We did a single-arm, phase 2 trial of patients recruited from the Dana–Farber/Harvard Cancer Center in the USA. Eligible patients had previously untreated acu...
1 CitationsSource
#1Jeffrey W. Craig (BC Cancer Agency)
#2Robert P. Hasserjian (Harvard University)H-Index: 45
Last. Elizabeth A. Morgan (Harvard University)H-Index: 21
view all 10 authors...
Greater than 90% of cases of systemic mastocytosis (SM) harbor pathogenic KIT mutations, particularly KITD816V. Prognostically-significant pathogenic KIT mutations also occur in 30–40% of core binding factor-associated acute myeloid leukemia (CBF-AML), but are uncommonly associated with concurrent SM. By comparison, the occurrence of SM in other myeloid neoplasms bearing pathogenic KIT mutations, particularly those with a chronic course, is poorly understood. Review of clinical next-generation s...
#1Jacqueline S. Garcia (Harvard University)H-Index: 8
#2Lillian Werner (Harvard University)H-Index: 22
Last. Robert J. Soiffer (Harvard University)H-Index: 95
view all 36 authors...
1 CitationsSource
#1Johannes GollH-Index: 18
#2R. Coleman Lindsley (Harvard University)H-Index: 22
Last. Matthew J. Walter (WashU: Washington University in St. Louis)H-Index: 34
view all 26 authors...
#1H. Moses Murdock (Harvard University)
#2Haesook T. Kim (Harvard University)H-Index: 57
Last. R. Coleman Lindsley (Harvard University)H-Index: 22
view all 20 authors...
#1T. A. KnudsenH-Index: 2
#2Vibe SkovH-Index: 9
Last. Ann Mullally (Broad Institute)H-Index: 23
view all 31 authors...
#1Jacqueline S. Garcia (Harvard University)H-Index: 8
#2Haesook T. Kim (Harvard University)H-Index: 57
Last. Joseph H. Antin (Harvard University)H-Index: 101
view all 21 authors...
1 CitationsSource
#1R. Coleman Lindsley (Harvard University)H-Index: 22
#2Christopher J. Gibson (Harvard University)H-Index: 17
Last. Jeffrey E. LancetH-Index: 37
view all 12 authors...